Merck KGaA announces out-licensing agreement with TrialSpark/High Line Bio for sprifermin for osteoarthritis.
Sprifermin, a recombinant form of human fibroblast growth factor 18, is currently being investigated in patients with osteoarthritis (OA). As part of the agreement, Merck will receive an upfront payment as well as equity in TrialSpark/High Line Bio and is eligible for milestone payments related to delivering on certain development and commercial milestones, in addition to royalties on any future net sales.
TrialSpark/High Line Bio will assume full responsibility for the research, development and commercialization of sprifermin, which is in Phase II studies.
Related news and insights
Novavax is awaiting US emergency use authorization for its prototype COVID-19 vaccine and is committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype vaccine offers broad immune responses including against circulating variants, such as the Omicron BA.4/5.